Quinupristin/dalfopristin, a new addition to the antimicrobial arsenal

Lancet

Volumn 354, Issue 9195, 1999, Pages 2012-2013

  Johnson, Alan P ^a   Livermore, David M ^a  

^a CENTRAL PUBLIC HEALTH LABORATORY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CEFAZOLIN; CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; OXACILLIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTHRALGIA; BACTERIAL INFECTION; CLINICAL TRIAL; DIARRHEA; EDEMA; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; INFLAMMATION; INTRAVENOUS DRUG ADMINISTRATION; MYALGIA; NOTE; PAIN; PRIORITY JOURNAL; RASH; THROMBOPHLEBITIS; VOMITING;

EID: 0033547637     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)00344-X     Document Type: Note

References (12)

1. Tomasz A. Multiple-antibiotic-resistant pathogenic bacteria: a report on the Rockefeller University Workshop. N Engl J Med. 330:1994;1247-1251.
2. Leclercq R., Courvalin P. Streptogramins: an answer to antibiotic resistance in gram-positive bacteria. Lancet. 352:1998;591-592.
3. Nadler H., Dowzicky M.J., Feger C., Pease M.R., Prokocimer P. Quinupristin/dalfopristin: a novel selective-spectrum antibiotic for the treatment of multi-resistant and other gram-positive pathogens. Clin Microbiol Newslett. 13:1999;103-112.
4. Tenover F.C., Lancaster M.V., Hill B.C.et al. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol. 36:1998;1020-1027.
5. Ploy M.C., Grélaud C., Martin C., de Lumley L., Denis F. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet. 351:1998;1212.
6. Nichols R.L., Graham D.R., Barriere S.L.et al. Treatment of hospitalised patients with complicated gram-positive skin and skin structure infections: two randomised, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. J Antimicrob Chemother. 44:1999;263-273.
7. Nichols R.L. Optimal treatment of complicated skin and skin structure infections. J Antimicrob Chemother. 44:1999;19-23. (suppl A).
8. Moellering R.C., Linden P.K., Reinhardt J., Blumberg E.A., Bompart F., Talbot G.H. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. J Antimicrob Chemother. 44:1999;251-261.
9. Moellering R.C. Quinupristin/dalfopristin: therapeutic potential for vancomycin-resistant enterococcal infections. J Antimicrob Chemother. 44:1999;25-30. (suppl A).
10. Rubinstein E., Prokocimer P., Talbot G.H. Safety and tolerability of quinupristin/dalfopristin: administration guidelines. J Antimicrob Chemother. 44:1999;37-46. (suppl A).
11. Low D.E., Nadler H.L. A review of in-vitro antibacterial activity of quinupristin/dalfopristin against methicillin-susceptible and -resistant Staphylococcus aureus. J Antimicrob Chemother. 39:1997;53-58. (suppl A).
12. Thal L.A., Zervos M.J. Occurrence and epidemiology of resistance to virginiamycin and streptogramins. J Antimicrob Chemother. 43:1997;171-176.